A new drug has shown significant potential in extending the lives of women with advanced endometrial cancer, according to results from a major international clinical trial. The medication, sacituzumab govitecan, developed by researchers at NYU Langone Health in New York, demonstrated a substantial reduction in the risk of disease progression and mortality among patients whose cancer had worsened despite previous chemotherapy and immunotherapy treatments.

Endometrial cancer, also known as womb cancer, ranks as the fourth most common cancer among women in the United Kingdom, with over 10,200 diagnoses annually. Its incidence and mortality rates have been rising globally, particularly among women under 50, where cases have doubled over the past quarter-century. Factors such as increasing obesity rates and delayed childbirth are believed to contribute to this upward trend.

Sacituzumab govitecan targets a protein that is expressed in high levels on many endometrial cancer cells. The drug works by binding to these cancer cells and delivering chemotherapy agents directly to the tumor, aiming to minimize damage to surrounding healthy tissue.

The phase III trial involved 776 women with endometrial cancer whose disease had progressed after standard treatments. Presented at the European Society of Medical Oncology's annual meeting in Madrid, the study found that patients receiving sacituzumab govitecan experienced a 41% lower risk of cancer progression compared to those treated with standard chemotherapy. Additionally, the risk of death from the disease was reduced by 32% in the group treated with the new drug.

These findings highlight sacituzumab govitecan's potential to become a new standard of care for patients with endometrial cancer resistant to existing treatments, offering a promising option where effective therapies have been limited. Further studies and regulatory evaluations will be needed before the medication is widely adopted in clinical practice.